Whitehawk Therapeutics
WHWK
65 hedge funds and large institutions have $16.7M invested in Whitehawk Therapeutics in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 16 closing their positions.
180% more call options, than puts
Call options by funds: $14K | Put options by funds: $5K
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
8% more funds holding
Funds holding: 60 → 65 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7.08% less ownership
Funds ownership: 53.81% → 46.73% (-7.1%)
36% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 22
46% less capital invested
Capital invested by funds: $30.9M → $16.7M (-$14.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$618K |
| 2 |
Millennium Management
New York
|
+$419K |
| 3 |
Jane Street
New York
|
+$249K |
| 4 |
Goldman Sachs
New York
|
+$194K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.34M |
| 2 |
DC
Decheng Capital
Menlo Park,
California
|
-$1.23M |
| 3 |
Morgan Stanley
New York
|
-$740K |
| 4 |
State Street
Boston,
Massachusetts
|
-$568K |
| 5 |
SO
STRS Ohio
Columbus,
Ohio
|
-$363K |
WHWK Hedge Fund Activity: Q2 2024 in Review
65 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q2 2024, worth a combined $16.7M — down 46% from $30.9M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new WHWK positions and 16 closed out — a net gain of 5 holders — while 14 added to existing stakes and 22 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $618K. The largest seller was BlackRock, cutting an estimated $1.34M.
- 65 institutional investors held Whitehawk Therapeutics (WHWK) as of Q2 2024, up from 60 in Q1 2024.
- Funds reported $16.7M of Whitehawk Therapeutics stock for Q2 2024, down 46% quarter-over-quarter.
- 21 funds opened new Whitehawk Therapeutics positions in Q2 2024 and 16 closed out, a net change of +5 holders.
- The largest Whitehawk Therapeutics buyer in Q2 2024 was Soleus Capital Management, an estimated $618K added.
- The largest Whitehawk Therapeutics seller in Q2 2024 was BlackRock, an estimated $1.34M sold.
Based on aggregated 13F filings for Q2 2024.